drugset / Trial / NCT06483347
Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This trial is designed to investigate the safety, response rates and survival outcomes of patients with inoperable lung cancer by infusion of CTLA4, PD1 and PDL1 antibodies combination with chemodrug or/and bevacizumab through intra-tumor (IT).
Timeline
- Start
- 2024-04-04
- Primary completion
- 2028-12-30
- Completion
- 2033-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Other |
| Subject | Durvalumab | Monoclonal antibody | — | Other |
| Subject | Idarubicin | Small molecule | — | Other |
| Subject | Ipilimumab | Monoclonal antibody | — | Other |
| Subject | Pembrolizumab | Monoclonal antibody | — | Other |